Share

Clinical Studies (1)

  • SOLIDARITY Finland Plus Long-COVID : Study aims to assess the long-term effects of imatinib and infliximab, used during acute hospitalisation due to COVID-19-infection, on long-COVID symptoms and quality of life using questionnaires at six months, one and two years post-discharge

Study Data

  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Post COVID-19 condition
  • Pharmacological intervention
  • Monoclonal antibodies
  • Immunomodulator
  • Antineoplastic agent
  • Imatinib
  • Infliximab

Other information

If you would like to contact the site, please email: ccb@ateneo.univr.it

The data is updated up to